<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138806">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294020</url>
  </required_header>
  <id_info>
    <org_study_id>PMR-EC-1206</org_study_id>
    <secondary_id>2010-020925-42</secondary_id>
    <nct_id>NCT01294020</nct_id>
  </id_info>
  <brief_title>Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®</brief_title>
  <official_title>A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf® Based Immunosuppressive Regimen, Including a Long-Term Follow-Up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conversion of stable pediatric allograft recipients from Prograf® immunosuppression to
      Advagraf® immunosuppression to compare exposure and follow for safety and efficacy over one
      year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part C: Continuation of long-term follow-up (from Day 365 onwards). Patients who have
      completed Part B and to whom continued treatment with Advagraf® is not currently available,
      will be offered participation in a continuation of long-term follow-up Part C. Part C will
      continue until Advagraf® becomes available to these patients or these patients'
      discontinuation, whichever is the earliest.

      This applies to patients in the following countries: Czech Republic, Germany, Italy and
      Poland only.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine steady state systemic exposure (AUC0-24h)</measure>
    <time_frame>day 7 and day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine Cmax (maximum concentration)</measure>
    <time_frame>day 7 and day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determine tmax (time to attain Cmax)</measure>
    <time_frame>day 7 and day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determine C24 (concentration prior to morning dose)</measure>
    <time_frame>day 7 and day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rejection episodes</measure>
    <time_frame>up to 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subject survival</measure>
    <time_frame>up to 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft survival</measure>
    <time_frame>up to 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of safety through the evaluation of Adverse Events, laboratory parameters and vital signs</measure>
    <time_frame>up to 54 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Intestine Transplantation</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Lung Transplantation</condition>
  <condition>Liver Transplantation</condition>
  <condition>Heart Transplantation</condition>
  <arm_group>
    <arm_group_label>Conversion from Prograf to Advagraf</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advagraf</intervention_name>
    <description>Oral</description>
    <arm_group_label>Conversion from Prograf to Advagraf</arm_group_label>
    <other_name>tacrolimus modified release</other_name>
    <other_name>MR4</other_name>
    <other_name>FK506E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>Oral</description>
    <arm_group_label>Conversion from Prograf to Advagraf</arm_group_label>
    <other_name>tacrolimus</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be able to swallow intact study medication capsules

          -  Received a single solid organ transplant at least 6 months prior to entry into the
             study

          -  The subject's parent(s), or their legal representative(s), has been fully informed
             and has given written informed consent to participate in the study. The subject has
             given assent where applicable

          -  Has been receiving a Prograf® based immunosuppressive regimen for a minimum of 3
             months

          -  Negative pregnancy test prior to enrolment (females)

          -  Must agree to practice effective birth control during the study

          -  Stable whole blood trough levels of tacrolimus in the range of 3.5 - 15ng/mL
             (+/-0.5ng/mL) and clinically stable in the opinion of the Investigator

        Exclusion Criteria:

          -  Previously received a multiple organ transplant

          -  Any rejection episode within 3 months prior to enrolment or within the last 6 months
             that required anti-lymphocyte antibody therapy, or 2 or more rejection episodes
             within the last 12 months

          -  Currently receiving Rapamycin, Certican or MPA (Myfortic®)

          -  Chronic dysfunction of the allograft, in the opinion of the Investigator

          -  Major changes in their immunosuppressive regimen within the last 3 months prior to
             entry into the study

          -  The subject is pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site AT11</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE21</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE22</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42</name>
      <address>
        <city>Prague 5</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR35</name>
      <address>
        <city>BRON Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR34</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR31</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR32</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE41</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT74</name>
      <address>
        <city>Bergamo</city>
        <zip>25127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT73</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT75</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT71</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT72</name>
      <address>
        <city>Rome</city>
        <zip>165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL51</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL52</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB61</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB64</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB62</name>
      <address>
        <city>Manchester</city>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>February 3, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transplant</keyword>
  <keyword>Liver</keyword>
  <keyword>Kidney</keyword>
  <keyword>Heart</keyword>
  <keyword>Lung</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Advagraf</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
